BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
最近の投稿
- 1
Tire Brands for Senior Drivers: Guaranteeing Security and Solace - 2Gaza humanitarian efforts reach key milestone as UNICEF vaccinates some 13,000 children
- 3Without evidence, CDC changes messaging on vaccines and autism
- 4Elite Execution Wall televisions for Film Darlings
- 5Discussion on deployment of foreign troops ongoing, two sources tell 'Post'
- Public Parks in the USA
- Rediscovering Experience Through Excursions: Individual Travel Stories
- Roche breast cancer pill cuts risk of disease recurrence by 30% in trial
- Figure out How to Improve Your Stream Voyage with Remarkable Trips and Exercises
- Roman around the Christmas tree | Space photo of the day for Dec. 25, 2025
- Make your choice for the PS5 game that you love playing with companions!
- Wellness Bits of knowledge Readily available: A Survey of \Following Wellbeing and Progress\ Wellness Wearables
- German finance minister seeks better market access in China talks
- Figure out How to Pick the Right Toothbrush for You
